Buradasınız

Adrenomedüllin ve Etkileri

Adrenomedullin and Its Properties

Journal Name:

Publication Year:

Key Words:

Keywords (Original Language):

Abstract (2. Language): 
Adrenomedullin (ADM) is a vasodilator peptide including 52 amino acids, first extracted from feocromastoma tissue in 1993. ADM was synthesized in many tissues mainly adrenal medulla, myocard, lungs, central nervous system and endothelial and vascular smooth muscle cells. Receptor activity modifying protein (RAMP) is required for normal function of specific receptors of calcitonin receptor like- receptor (CRLR) on the cell membrane. ADM has various biological activities on many tissues and its effects on all systems were investigated. The principal characteristic effect of ADM is to lower the systemic arterial blood pressure. In addition, it inhibits the cell migration and has natriureatic and antiproliferative effects. In cases of arterial hypertension, acute coronary syndrome, heart failure, renal diseases and septic shock, plasma levels of ADM was found to be markedly increased.
Abstract (Original Language): 
İlk kez 1993 yılında feokromasitoma dokusundan izole edilmiş olan adrenomedüllin (ADM) 52 aminoasit içeren vazodilatatör bir peptidtir. ADM başlıca adrenal medullada olmak üzere miyokard, akciğerler, santral sinir sistemi, endotel ve vasküler düz kas hücreleri gibi birçok dokuda sentezlenmektedir. Kalsitonin reseptör benzeri reseptör (CRLR) adı verilen spesifik reseptörünün hücre membranında fonksiyon göstermesi için reseptör aktivite düzenleyici protein (RAMP) isminde bir proteine ihtiyacı bulunmaktadır. ADM birçok dokuda çeşitli biyolojik aktivitelere sahiptir ve tüm sistemler üzerindeki etkileri ayrıntılı olarak incelenmiştir. Temel karakteristik etkisi sistemik arteriyel basıncı düşürmesidir. Ayrıca natriüretik, antiproliferatif ve hücre migrasyonunu inhibe edici özelliklere sahiptir. Arteriyel hipertansiyon, akut koroner sendrom, kalp yetmezliği, böbrek hastalıkları ve septik şok gibi patofizyolojik durumlarda plazma ADM seviyesinin yükseldiği saptanmıştır.
127-132

REFERENCES

References: 

1. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura
S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive
peptide isolated from human pheochromocytoma. Biochem
Biophys Res Commun 1993;192: 553–60.
2. Kapas S, Martinez A, Cuttitta F, Hinson JP. Local production
and action of adrenomedullin in the rat adrenal zona
glomerulosa. J Endocrinol 1998;156:477–84.
3. Wimalawansa SJ. Amylin, calcitonin gene-related peptide,
calcitonin, and adrenomedullin: a peptide superfamily. Crit
Rev Neurobiol 1997;11:167–239.
4. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP:
Discovery, structures and cardiovascular functions. Microsc
Res Tech 2002;57:3–13.
5. Joy P H, Supriya K, David M S. Adrenomedullin, a
multifunctional regulatory peptide. Endocr Rev 2000;21:138–
67.
6. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H
is a serumbinding protein for adrenomedullin and the resulting
complex modulates the bioactivities of both partners. J Biol
Chem 2001;276:12292–300.
7. Hirayama N, Kitamura K, Imamura T, et al. Secretion and
clearance of the mature form of adrenomedullin in humans.
Life Sci 1999;64:2505–9.
8. Minamino N, Kikumoto K, Isumi Y. Regulation of
adrenomedullin expression and release. Microsc Res Tech
2002;57:28– 39.
9. Horio T, Nishikimi T, Yoshihara F, et al. Production and
secretion of adrenomedullin in cultured rat cardiac myocytes
and nonmyocytes: stimulation by interleukin-1 beta and tumor
necrosis factor-alpha. Endocrinology 1998;139:4576–80.
10. Tomoda Y, Kikumoto K, Isumi Y, et al. Cardiac fibroblasts
are major production and target cells of adrenomedullin in the
heart in vitro. Cardiovasc Res 2001;49:721–30.
11. Shan J, Stachniak T, Jhamandas JH, Krukoff TL. Autonomic
and neuroendocrine actions of adrenomedullin in the brain:
mechanisms for homeostasis. Regul Pept 2003;112:33– 40.
12. Autelitano DJ, Ridings R, Pipolo L, Thomas WG.
Adrenomedullin inhibits angiotensin AT1A receptor
expression and function in cardiac fibroblasts. Regul Pept
2003;112:131–7.
13. Charles CJ, Lainchbury JG, Nicholls MG, et al.
Adrenomedullin and the renin–angiotensin–aldosterone
system. Regul Pept 2003;112:41-9.
14. Lainchbury JG, Troughton RW, Lewis LK, et al.
Hemodynamic, hormonal, and renal effects of short-term
adrenomedullin infusion in healthy volunteers. J Clin
Endocrinol Metab 2000; 85:1016–20.
15. Vesely DL, Blankenship M, Douglass MA, et al. Atrial
natriuretic peptide increases adrenomedullin in the circulation
of healthy humans. Life Sci 1996;59:243–54.
16. Marutsuka K, Hatakeyama K, Yamashita A, et al.
Adrenomedullin augments the release and production of tissue
factor pathway inhibitor in human aortic endothelial cells.
Cardiovasc Res 2003; 57:232–7.
17. Tsuruda T, Kato J, Kitamura K, et al. Enhanced
adrenomedullin production by mechanical stretching in
cultured rat cardiomyocytes. Hypertension 2000;35:1210–4.
18. Hague S, Zhang L, Oehler MK, et al. Expression of the
hypoxically regulated angiogenic factor adrenomedullin
correlates with uterine leiomyoma vascular density. Clin
Cancer Res 2000;6:2808–14.
19. Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases
vascular adrenomedullin expression. Biochem Biophys Res
Commun 1999;258:453–6.
20. Nakayama M, Takahashi K, Murakami O, Et Al.
Adrenomedullin in monocytes and macrophages. Possible
involvement of macrophage-derived adrenomedullin in
atherogenesis. Clin Sci 1999;97:247-51.
21. Von der HK, Kandler MA, Popp K, et al. Aerosolized
adrenomedullin suppresses pulmonary transforming growth
factor-beta1 and interleukin-1 beta gene expression in vivo.
Eur J Pharmacol 2002;457:71– 6.
22. Minami K, Segawa K, Uezono Y, et al. Adrenomedullin
inhibits the pressor effects and decrease in renal blood flow
induced by norepinephrine or angiotensin II in anesthetized
rats. Jpn J Pharmacol 2001;86:159–64.
23. Nishikimi T, Kitamura K, Saito Y, et al. Clinical studies on
the sites of production and clearance of circulating
adrenomedullin in human subjects. Hypertension
1994;24:600–4.
24. Choksi T, Hay DL, Legon S, et al. Comparison of the
expression of calcitonin receptorlike receptor (CRLR) and
receptor activity modifying proteins (RAMPs) with CGRP and
adrenomedullin binding in cell lines. Br J Pharmacol
2002;136:784–92.
25. Debbie LH, David MS. ADM reseptors: molecular identity
and function. Peptides 2001;22:1753-63.
26. Morfis M, Christopoulos A, Sexton PM. RAMPs: 5 years on,
where to now? Trends Pharmacol Sci 2003; 24(11):596– 601.
27. Chakravarty P, Suthar TP, Coppock HA, et al. CGRP and
adrenomedullin binding correlates with transcript levels for
calcitonin receptor-like receptor (CRLR) and receptor activity
modifying proteins (RAMPs) in rat tissues. Br J Pharmacol
2000;130:189–95.
28. Fung E, Fiscus RR. Adrenomedullin induces direct
(endothelium-independent) vasorelaxations and cyclic
adenosine monophosphate elevations that are synergistically B.Ç. Etöz, ark.
132
enhanced by brain natriuretic peptide in isolated rings of rat
thoracic aorta. J Cardiovasc Pharmacol 2003;41:849–55.
29. Hirata Y, Hayakawa H, Suzuki Y, et al. Mechanisms of
adrenomedullin-induced vasodilation in the rat kidney.
Hypertension 1995;25:790–5.
30. DeMatteo R, May CN. Direct coronary vasodilator action of
adrenomedullin is mediated by nitric oxide. Br J Pharmacol
2003;140:1414–20.
31. Nishimatsu H, Suzuki E, Nagata D, et al. Adrenomedullin
induces endothelium dependent vasorelaxation via the
phosphatidylinositol 3-kinase/Akt-dependent pathway in rat
aorta. Circ Res 2001;89:63–70.
32. Terata K, Miura H, Liu Y, Loberiza F, Gutterman DD. Human
coronary arteriolar dilation to adrenomedullin: role of nitric
oxide and K
+
channels. J Physiol Heart Circ Physiol
2000;279:H2620–6.
33. Kato K, Yin H, Agata J, et al. Adrenomedullin gene delivery
attenuates myocardial infarction and apoptosis after ischemia
and reperfusion. J Physiol Heart Circ Physiol
2003;285:H1506-14.
34. Zhang XP, Tada H, Wang Z, Hintze T. cAMP signal
transduction, a potential compensatory pathway for coronary
endothelial NO production after heart failure. Arterioscler
Thromb Vasc Biol H 2002;22:1273–8.
35. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of
adrenomedullin through activation of Akt, mitogen-activated
protein kinase, and focal adhesion kinase in endothelial cells.
FASEB J 2003; 17:1937-9.
36. Del BR, Lazzeri C, Barletta G, et al. Effects of low-dose
adrenomedullin on cardiac function and systemic
haemodynamics in man. Clin Physiol 2000;20:457–65.
37. Shichiri M, Fukai N, Ozawa N, Iwasaki H, Hirata Y.
Adrenomedullin is an autocrine/paracrine growth factor for rat
vascular smooth muscle cells. Regul Pept 2003;112:167–73.
38. Kano H, Kohno M, Yasunari K, et al. Adrenomedullin as a
novel antiproliferative factor of vascular smooth muscle cells.
J Hypertens 1996;14:209–13.
39. Limuro S, Shindo T, Moriyama N, et al. Angiogenic effects of
adrenomedullin in ischemia and tumor growth. Circ Res
2004;95:415-23.
40. Wolf K, Kurtz A, Pfeifer M, et al. Different regulation of left
ventricular ANP, BNP and adrenomedullin mRNA in the
twokidney, one-clip model of renovascular hypertension.
Pflugers Arch 2001;442:212–7.
41. Nakamura R, Kato J, Kitamura K, et al. Beneficial effects of
adrenomedullin on left ventricular remodeling after
myocardial infarction in rats. Cardiovasc Res 2002;56:373–
80.
42. Mukherjee R, Multani MM, Sample JA, et al. Effects of
adrenomedullin on human myocyte contractile function and
beta-adrenergic response. J Cardiovasc Pharmacol Ther
2002;7:235–40.
43. Luodonpaa M, Rysa J, Pikkarainen S, et al. Mechanisms
regulating adrenomedullin gene expression in the left
ventricle: role of mechanical load. Regul Pept 2003;112(1-
3):153–9.
44. Eto T, Kato J, Kitamura K. Regulation of production and
secretion of adrenomedullin in the cardiovascular system.
Regul Pept 2003;112:61–9.
45. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma
adrenomedullin as an indicator of prognosis after acute
myocardial infarction. Heart 1999;81:483–7.
46. Nicholls MG, Lainchbury JG, Lewis LK, et al. Bioactivity of
adrenomedullin and proadrenomedullin N-terminal 20 peptide
in man. Peptides 2001;22:1745–52.
47. Charles CJ, Rademaker MT, Richards AM, et al.
Hemodynamic, hormonal, and renal effects of
intracerebroventricular adrenomedullin in conscious sheep.
Endocrinology 1998;139:1746–51.
48. Hamid SA, Baxter GF. ADM: Regulator of systemic and
cardiac homeostasis in acut myocardial infarction. Pharmacol
Ther 2005;105:95-112.
49. Hamid SA, Baxter GF. Adrenomedullin limits infarct size at
reperfusion. J Mol Cell Cardiol 2004;36:731.
50. Serrano J, Encinas JM, Fernandez AP, et al. Distribution of
immunoreactivity for the adrenomedullin binding protein,
complement factor H, in the rat brain. Neuroscience
2003;116:947–62.
51. Troughton RW, Frampton CM, Lewis LK, et al. Differing
thresholds for modulatory effects of adrenomedullin infusion
on haemodynamic and hormone responses to angiotensin II
and adrenocorticotrophic hormone in healthy volunteers. Clin
Sci Lond 2001;101:103–9.
52. Fukuhara M, Tsuchihashi T, Abe I, Fujishima M.
Cardiovascular and neurohormonal effects of intravenous
adrenomedullin in conscious rabbits. Am J Physiol
1995;269:R1289–93.
53. Ohbayashi H, Suito H, Yoshida N, et al. Adrenomedullin
inhibits albumin-induced bronchoconstriction and airway
microvascular leakage in guinea pigs. Eur Resp J
1999;14:1076–81.
54. Kaneko H, Mitsuma T, Nagai H, et al. Central action of
adrenomedullin to prevent ethanol-induced gastric injury
through vagal pathways in rats. Am J Physiol
1998;274:R1783–8.
55. Upton PD, Austin C, Taylor GM, et al. Expression of ADM
and its binding sites in the rat uterus: increased number of
binding sites and ADM messenger ribonucleic acid in 20-day
pregnant rats compared with nonpregnant rats. Endocrinology
1997;138:2508–14.
56. Garayoa M, Bodegas E, Cuttitta F, Montuenga LM.
Adrenomedullin in mammalian embryogenesis. Microsc Res
Technique 2002;57:40–54.
57. Pio R, Martinez A, Elsasser TH, Cuttitta F. Presence of
immunoreactive adrenomedullin in human and bovine milk.
Peptides 2000;21:1859–63.
58. Allaker RP, Zihni C, Kapas S. An investigation into the
antimicrobial effects of adrenomedullin on members of the
skin, oral, respiratory tract and gut microflora. FEMS
Immunol Med Microbiol 1999;23:289-93.
59. Allaker RP, Kapas S. Adrenomedullin and mucosal defence:
interaction between host and microorganism. Regul Pept
2003;112:147–52.
60. Hippenstiel S, Witzenrath M, Schmeck B, et al.
Adrenomedullin reduces endothelial hyperpermeability. Circ
Res 2002;91(7):618–25.
61. Yang S, Zhou M, Fowler DE, Wang P. Mechanisms of the
beneficial effect of adrenomedullin and adrenomedullinbinding protein- 1 in sepsis: down-regulation of
proinflammatory cytokines. Crit Care Med 2002;30:2729–35.

Thank you for copying data from http://www.arastirmax.com